Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon to Develop Cancer Markers for OncoMethylome

NEW YORK (GenomeWeb News) — OncoMethylome Sciences has tapped Rubicon Genomics to identify and analyze biomarkers that may lead to early cancer detection tests, Rubicon said today.
 
Under the collaboration, Rubicon will use its MethylPlex platform, which identifies multi-gene patterns of abnormal DNA methylation that arise during tumor development, to develop markers that predict the presence of cancer. The agreement also gives OncoMethylome an option to license markers that result from the collaboration.
 
Rubicon said it has already licensed a set of biomarkers to OncoMethylome resulting from a similar, earlier agreement.
 
Financial terms of the agreement were not released.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.